Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population

  title={Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population},
  author={Jussi Aro},
  journal={The Prostate},
  • J. Aro
  • Published 1991
  • Medicine
  • The Prostate
Four hundred and seventy‐seven prospectively randomized patients with prostatic carcinoma were treated with a combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol, with intramuscular PEP alone, or with orchiectomy. The cardiovascular and all‐cause mortality of the two estrogen therapy modalities and orchiectomy were compared with those of the Finnish male population in general. The age‐standardized rate ratios (∼ relative risk) for cardiovascular mortality and… 

Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.

Parenteral PEP (240 mg/month) seems to be as efficient as orchidectomy in inhibiting disease in patients with advanced prostatic cancer, and the difference was statistically significant during the first year of treatment.

Gastrectomy for Early Gastric Cancer is Associated with Decreased Cardiovascular Mortality in Association with Postsurgical Metabolic Changes

Patients with EGC who undergo gastrectomy have a lower cardiovascular mortality but similar all-cause mortality as that of the general population, and a significant reduction in body weight and visceral fat after surgery may improve impaired lipid metabolism and prevent atherosclerotic changes.

Transdermal estradiol therapy for advanced prostate cancer--forward to the past?

Transdermal estradiol therapy prevented andropause symptoms, improved quality of life scores and increased bone density, with the potential for considerable economic savings over conventional hormone therapies.

Advanced Prostate Cancer

The aim of intermittent androgen suppression is to increase quality of life during treatment-free periods and to maintain the androgen dependency of the malignant cells.

Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy

Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause, which are induced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia and cognitive dysfunction.


Comparing the efficacy, complications and cost of regimens containing oral estrogens or parented estrogens with agents that increase efficacy and decrease toxicity to results of other regimens, such as combined androgen blockade, should be done to determine if an estrogencontaining regimen could lower the cost of treating advanced prostate cancer.

androgen deprivation therapy for prostate cancer - the potential of parenteral estrogen

Parenteral estrogen therapy is protection against the effects of the andropause (cf female menopause), which with conventional androgen suppression causes significant morbidity including osteoporotic fracture, hot flushes, lethargy and cognitive dysfunction.

Estrogens in the treatment of prostate cancer.

Parenteral oestrogen in the treatment of prostate cancer: a systematic review

The results provide no evidence to suggest that parenteral oestrogen, in doses sufficient to produce castrate levels of testosterone, is less effective than luteinising hormone-releasing hormone (LHRH) or orchidectomy in controlling prostate cancer, or that it is consistently associated with an increase in cardiovascular mortality.



Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.

Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease, venous thromboembolism, cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment.

Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.

The substantially increased risk of cardiovascular complications in patients given oestrogen for prostatic cancer warrants careful consideration when choosing treatment for this disorder.

Cardiovascular complications in the treatment of prostatic carcinoma.

It is recommended that stilboestrol and estramustine phosphate should not be used in the presence of cardiovascular disease and that the primary form of treatment in prostatic carcinoma should be bilateral orchiectomy, especially in patients with localised disease.

Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate

Patients treated with a 5.0‐mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non‐fatal cardiovascular disease when compared to placebo in all stages of prostatic

Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol.

  • G. Jönsson
  • Medicine
    Scandinavian journal of urology and nephrology
  • 1971
Combined treatment with Estradurin and a stronger inhibitor of gonadotropin might be more effective in patients with prostatic carcinoma, which has a firm diagnosis of carcinoma.

Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.

During the 4-year follow-up period there were no significant differences in the progression rates and the frequency of thromboembolic and other cardiovascular complications was highest in the estrogen group, while in the radiotherapy group, 19 of 45 patients had bowel or bladder complications.

Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate

Patients with cancer of the prostate treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections have responded to therapy and there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months.

Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.

PEP treatment caused changes in the serum lipoprotein pattern, which apparently decreases the risk of atherosclerosis.

High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.

It was concluded that parenteral high dose PEP is not associated with an increased risk of cardiovascular complications and there is no need for daily low dose ASA.

The veterans administration cooperative urological research group's studies of cancer of the prostate

The overall recommendation at present is that patients with prostatic cancer should not be treated until their symptoms require relief, and at that time it is recommended starting treatment with 1.0 mg DES daily.